Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
AssigneeLumos Pharma, Inc.
InventorsMichael Oliver THORNER, Roy G. Smith
Life of this patent
Estimating the term…
Abstract
Described herein is a new method for treating diseases such as no«--alcoholic fatty liver disease and non-alcoholic steatohepatius with a growth hormone secretagogue alone or in combination with a drug selected from a dipeptidyl peptidase-4 antagonist a glucagon-like peptide receptor agonist, a thrazolidinedione, a sodium glucose transport protein 2 antagonist, arid metformin. Compositions relating to the same are also provided.
Claims28
A method of treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatits (NASH), comprising:
- administering to a patient in need thereof a therapeutically effective amount of a growth hormone secretagogue (GHS).
A method of treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatits (NASH), comprising the steps of administering to a patient in need thereof:
- a therapeutically effective amount of a growth hormone secretagogue (GHS);
- and
- a therapeutically effective amount of a second drug selected from dipeptidyl peptidase-4 (DPP4) antagonist, a glucagon-like peptide (GLP-1) receptor agonist, a thiazolidinedione, a sodium glucose transport protein 2 (SGLT2) antagonist, metformin and vitamin E.
A method of treating NAFLD or NASH, comprising:
- administering to a patient in need thereof:
- a a therapeutically effective amount of a growth hormone secretagogue (GHS);
- b a therapeutically effective amount of a second drug selected from:
- a dipeptidyl peptidase-4 (DPP4) antagonist, a glucagon-like peptide (GLP-1) receptor agonist, a thiazolidinedione, and, a sodium glucose transport protein 2 (SGLT2) antagonist;
- and,
- c a therapeutically effective amount of a third drug, which is metformin.
The method of claim 19, wherein the therapeutically effective amount of ibutamoren is 25-50 mg/day.
The method of claim 19, wherein the GHS is ibutamoren and the second drug is sitagliptin.
The method of claim 19, wherein the GHS is ibutamoren and the second drug is pioglitazone.
A drug composition, comprising:
- a a therapeutically effective amount of a GHS;
- b a therapeutically effective amount of a second drug selected from:
- a DPP4 antagonist, a thiazolidinedione, a SGLT2 antagonist, metformin and vitamin E;
- and,
- c a pharmaceutically acceptable carrier;
- wherein the composition is useful in treating NAFLD and/or NASH.
A drug composition, comprising:
- a a therapeutically effective amount of a GHS;
- b a therapeutically effective amount of a second drug selected from:
- a DPP4 antagonist, a thiazolidinedione, and a SGLT2 antagonist;
- c a therapeutically effective amount of a third drug, which is metformin;
- and,
- d a pharmaceutically acceptable carrier;
- wherein the composition is useful in treating NAFLD and/or NASH.
Dependencies are inferred from the claim text.